Evidence map›Paper›PMID 34853812›Full record

ArticleMolecular therapy oncolytics2021

Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy.

Jin Meng, Emmanuel Deshayes, Li Zhang, Wei Shi, Xiaomeng Zhang, Xingxing Chen, Xin Mei, Jinli Ma, Yizhou Jiang, Jiong Wu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy oncolytics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Jin MengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Emmanuel DeshayesInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut régional du Cancer de Montpellier (ICM), University of Montpellier, 34298 Montpellier Cedex 5, France.
Li ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Wei ShiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiaomeng ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xingxing ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xin MeiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jinli MaDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yizhou JiangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Jiong WuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhimin ShaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaoli YuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zhaozhi YangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiaomao GuoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shanghai Medical College of Fudan University · CNInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy (RT) is a major modality of postoperative treatment in breast cancer. The maximal standardized value (SUVmax) is

Indexed as

breast cancerFDG uptakegene signatureimmunosuppressionradiotherapy

Identifiers

PMID34853812
PMCPMC8605077
OpenAlexW3208005710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.